New hope for kids with stubborn histiocytosis: vemurafenib dose trial launched
NCT ID NCT04943198
First seen Apr 10, 2026 · Last updated May 15, 2026 · Updated 6 times
Summary
This study is for children with a rare disease called histiocytosis that has not improved with standard treatments and who have a specific gene change (BRAF mutation). The goal is to find the best dose and timing of the drug vemurafenib to control the disease. About 25 children will take part, and researchers will track how long they stay free of disease worsening or relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HISTIOCYTOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mother and Child Institute
RECRUITINGWarsaw, Mazovian, 01-211, Poland
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.